Bulletin of the Medical Social Institute of Tajikistan, 2025, № 1, с. 46-50
Use of Visanne in adenomyosis
Аннотация · Abstract
Purpose of the study. To determine the efficacy of dienogest (Vizanne) at a dose of 2 mg in the treatment of premenopausal patients with adenomyosis.Material and research methods. We examined 21 women in the gynecology department of the Research Institute of Obstetrics, gynecology and Perinatology, aged from 39 to 49 years, suffering from adenomyosis, complicated by menstrual dysfunction and pelvic pain syndrome. The inclusion criteria for the study were the absence of indications for surgical treatment, diffuse and local adenomyosis .Results of the study and their discussion. The effectiveness of treatment with dienogest (Vizanne) at a dose of 2 mg for 6 months in relation to the therapy of endometriosis in women of these age groups has been proven clinically, which was characterized by the absence of pain syndrome and acyclic menstrual bleeding. Ultrasound examination of the pelvic organs showed a decrease in the severity of adenomyosis. After 6 months of treatment, all patients showed stable remission of the disease and amenorrhea.Conclusion. Conducted studies indicate that the use of the antiproliferative drug Visanne can reduse hysterotopic endometrial inclusions in the myometrium, improve the state of myometrial architecture and thereby alleviate the clinical manifestations of the disease, accompanied by debilitating pelvic pain.
Сведения · Details
- Журнал · Journal Bulletin of the Medical Social Institute of Tajikistan
- Язык · Language английский
- Цитирования (Crossref) · Citations 0